Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
– Clinical supply agreement with AstraZeneca for global Phase 1b/2 study to evaluate the safety and early efficacy of etakafusp alfa (AB248) in combination with rilvegostomig as a first-line treatment in patients with advanced or metastatic NSCLC –
— 與阿斯利康簽訂了全球1b/2期研究的臨牀供應協議，該研究旨在評估依塔卡富斯普阿法（AB248）與rilvegostomig聯合用作晚期或轉移性非小細胞肺癌患者一線治療的安全性和早期療效 —
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an agreement with AstraZeneca (NASDAQ:AZN) to supply etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, to be evaluated in combination with rilvegostomig, AstraZeneca's investigational PD-1/TIGIT immuno-oncology bispecific antibody, in patients with advanced or metastatic NSCLC.
開發癌症和傳染病精確靶向免疫療法的生物技術公司Asher Biotherapeutics今天宣佈與阿斯利康（納斯達克股票代碼：AZN）達成協議，提供艾塔卡福斯阿爾法（前身爲 AB248），這是Asher Bio的研究性CD8+ T細胞靶向白介素-2（IL-2）免疫療法，將與阿斯利康 rilvegostomig 聯合進行評估在研的PD-1/Tigit免疫腫瘤學雙特異性抗體，適用於晚期或轉移性非小細胞肺癌患者。